FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product

Summary

The FDA has awarded a priority review voucher to EVRYSDI, the sponsor of the rare pediatric disease product risdiplam, manufactured by Genentech Inc., following a review of the product's eligibility under the FD&C Act and FDASIA.